BioCentury
ARTICLE | Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

June 15, 2018 6:19 PM UTC

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or metastatic solid tumors. The once-weekly 4 mg dose of AL101, the maximum tolerated dose (MTD), also led to partial responses in one patient with a desmoid tumor and one patient with adenoid cystic carcinoma. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The most common grade 3/4 adverse events reported were diarrhea, hypophosphatemia, nausea, vomiting and hypokalemia. The open-label, international trial enrolled 94 patients to receive AL101 every week or every two weeks...